Geron Corporation (GERN)

GERN Oncology

BiotechSign Signal Grade

D
Signal Grade
48.1/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
100
Dilution Risk
50
Clinical Activity
75
Short Interest
50

Pipeline Overview

Therapeutic Focus
Oncologysrc

Clinical Trial Activity

5
Clinical Trials
(ClinicalTrials.gov aggregate)
3 Phase 1, 1 Phase 2, 2 Phase 3
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK
3.4 months
Cash Runway Estimate
50/100
Dilution Score
29,293,291
Outstanding Warrants
15Warrant Risk
40Convertible Risk
40Offering Ability

Dilution score: 50/100 (MEDIUM), 3.4 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

13.79%
Float Shorted
7.4
Days to Cover
MODERATE
Squeeze Risk
-10.6%
SI Change
DECREASING
Trend
73,886,113
Shares Short

Short interest: 13.79% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Geron Corporation.

Full GERN Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.